Table 1 Baseline features of 168 patients analyzed.

Age, yr Mean (SD)	67.1 (11.5)
*Other includes: Neuroendocrine carcinoma (2), autoimmune pancreatitis (1), intrapancreatic spleen (1), lymphoid tissue (1), schwannoma (1) SD, standard deviation; PDAC, pancreatic ductal adenocarcinoma; NET, neuroendocrine tumor; CI, confidence interval.
Sex, N (%) Male Female	75 (44.7%) 93 (55.3%)
Tumor site, N (%) Uncinate process Head Neck Body Tail	16 (9.5%) 75 (44.6%) 10 (6%) 40 (23.8%) 27 (16.1%)
Tumor size, mm Mean (SD)	31.9 (12.2)
Biopsy route, N (%) Transgastric Transduodenal	84 (50.0%) 84 (50.0%)
Final diagnosis, N (%) PDAC NET Metastasis Inflammatory Other*	127 (75.5%) 18 (10.7%) 12 (7.1%) 5 (3.2%) 6 (3.5%)
Follow-up Median time, days (95% CI) Surgical resection, N (%)	212 (168–254) 39 (23.2%)